Cagrilintide

What Is Cagrilintide?

Cagrilintide is a novel investigational peptide classified as a long‑acting amylin analog. Developed by Novo Nordisk A/S, it is designed to mimic the physiological activity of endogenous amylin, a hormone co‑secreted with insulin from pancreatic β‑cells. Its therapeutic potential lies in appetite regulation, weight reduction, and metabolic control, making it a candidate for obesity and cardiometabolic disorder management.

Mechanism of Action

Cagrilintide binds selectively to amylin receptors (AMYR1–3) located in the hypothalamus and brainstem. This receptor activation enhances satiety signaling, reduces food intake, and delays gastric emptying through pathways distinct from GLP‑1 receptor agonism. By modulating the gut‑brain axis, Cagrilintide produces sustained appetite suppression and metabolic improvements, complementing existing incretin‑based therapies.

Research & Clinical Trial Data

Cagrilintide has been evaluated in multiple Phase II and Phase III clinical trials. Results demonstrate significant reductions in mean body weight compared to placebo, with additive effects when combined with GLP‑1 receptor agonists such as Semaglutide. Trials under the REDEFINE program highlight its role in long‑term weight management, cardiometabolic risk reduction, and potential adjunctive therapy for type 2 diabetes.

Purity & Quality

Reference‑grade peptide material. Certificate of Analysis available per batch. Regulatory status: investigational, not FDA‑ or EMA‑approved for therapeutic use.

Classification & Handling Class: Long‑acting amylin analog | Administration: Subcutaneous injection | Sponsor: Novo Nordisk A/S | Storage: 2–8°C refrigerated, protect from light | Regulatory: Investigational, clinical trial stage